A Fixed Dose Study of Ropinirole Prolonged Release as Adjunctive Treatment in Patients With Advanced Parkinson's Disease
A Fixed Dose, Dose-response Study of Ropinirole Prolonged Release (PR) as Adjunctive Treatment to L-dopa in Patients With Advanced Parkinson's Disease
Sponsor: GlaxoSmithKline
A PHASE4 clinical study on Parkinson Disease, this trial is completed. The trial is conducted by GlaxoSmithKline and has accumulated 9 data snapshots since 2012. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
9 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE4
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE4
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE4
-
Jul 2018 — Jan 2021 [monthly]
Completed PHASE4
▶ Show 4 earlier versions
-
Jun 2018 — Jul 2018 [monthly]
Completed PHASE4
-
Aug 2017 — Jun 2018 [monthly]
Completed PHASE4
-
Feb 2017 — Aug 2017 [monthly]
Completed PHASE4
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE4
First recorded
Apr 2012
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- GlaxoSmithKline
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Anyang-si, South Korea , Banská Bystrica, Slovakia , Boca Raton, United States , Bratislava, Slovakia , Buenos Aires, Argentina , Busan, South Korea , Caba, Argentina , Chelyabinsk, Russia , Ciudad Autonoma de Buenos Aires, Argentina , Ciudad Autónoma de Buenos Aires, Argentina and 31 more locations